Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

85.84B

Market cap85.84B

Price-Earnings ratio

20.36

Price-Earnings ratio20.36

Dividend yield

0.45%

Dividend yield0.45%

Average volume

672.90K

Average volume672.90K

High today

$843.15

High today$843.15

Low today

$825.00

Low today$825.00

Open price

$826.24

Open price$826.24

Volume

109.00K

Volume109.00K

52 Week high

$847.00

52 Week high$847.00

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 85.84B, Regeneron(REGN) trades at $833.73. The stock has a price-to-earnings ratio of 20.36 and currently yields dividends of 0.45%.

As of 2026-09-02, Regeneron(REGN) stock has fluctuated between $825.00 and $843.15. The current price stands at $833.73, placing the stock +1.1% above today's low and -1.1% off the high.

Regeneron(REGN) shares are trading with a volume of 109K, against a daily average of 672.9K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $847.00 and a 52-week low of $541.00.

REGN News

Investing.com 1d

RBC Capital maintains Regeneron stock rating on collaboration outlook - Investing.com

...

Simply Wall St 2d

Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has secured past FDA approval for Pasatru (garetosmab-grts), a VelocImmune-derived monoclonal antibody that reduces new heterotopic os...

Simply Wall St 7d

Veeva Systems Lands Two Global Vault CRM Customers

Veeva Systems (NYSE:VEEV) said Regeneron Pharmaceuticals and Biogen have selected Veeva Vault CRM for their global operations in new partnerships. The agreemen...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

33.3%

Sell

6.7%

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.